BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational BTK degrader bexobrutideg (NX-5948) in patients with relapsed or refractory Waldenström macroglobulinemia (WM), presented at the 67th American Society of Hematology (ASH) Annual Meeting. The results demonstrate a 75% objective response rate (ORR) in a heavily pre-treated population and show deepening, durable responses with continued treatment, underscoring the compound’s potential as a best-in-class targeted degrader therapy.
Science Significance
The new ASH data highlight the scientific importance of targeted protein degradation as a therapeutic strategy for B-cell malignancies. Bexobrutideg, a highly selective and brain-penetrant BTK degrader, showed VGPRs, partial responses, and durable disease control in a median follow-up of 8.1 months, with median duration of response (DOR) and progression-free survival (PFS) not yet reached. This is notable in a cohort where all patients had received prior BTK inhibitors, and many had MYD88 and CXCR4 mutations—historically challenging subsets. The absence of dose-limiting toxicities and a favorable safety profile further reinforce the mechanistic robustness and therapeutic promise of BTK degradation for resistant lymphomas.
Regulatory Significance
Although early-stage, the Phase 1 findings provide critical momentum for future regulatory pathways, particularly as the candidate advances into Phase 2 pivotal trials in chronic lymphocytic leukemia and ongoing Phase 1/1b studies in broader B-cell malignancies. The strong ORR of 75%, rising to 82.6% in certain subgroups, and a 100% disease control rate among evaluable patients offer the type of clinical signals regulators look for when assessing novel mechanisms such as degraders. The therapy’s consistent tolerability, including no Grade 5 adverse events and no atrial fibrillation—a common concern with traditional BTK inhibitors—strengthens confidence for future regulatory submissions and accelerated-development designations.
Business Significance
Advertisement
The results represent a strategic advancement for Nurix, a company built around AI-integrated degrader discovery platforms and a growing biopharmaceutical pipeline. Strong clinical activity in WM, combined with potential applications across CLL and other non-Hodgkin lymphoma indications, enhances the commercial trajectory of bexobrutideg and supports Nurix’s broader position in the targeted protein degradation market, an emerging multi-billion-dollar therapeutic category. The progress may positively influence investor confidence, strengthen existing collaborations with major industry partners, and elevate competitive positioning against next-generation BTK inhibitors and novel immune-modulating platforms.
Patients’ Significance
For patients with relapsed or refractory WM—many of whom have undergone multiple lines of therapy and exhibit mutations linked to poor outcomes—the emergence of a well-tolerated, orally bioavailable, brain-penetrant therapy is highly meaningful. The durable and deepening responses, including VGPRs even in mutation-positive populations, reflect the potential to address unmet needs where standard BTK inhibitors eventually fail. Additionally, the observed activity in patients with central nervous system involvement, where two of three responded, signals an important advance for a subset with very limited options.
Policy Significance
As degrader-based therapies transition into later-phase studies, policymakers and healthcare frameworks may need to adapt reimbursement models, clinical trial infrastructure, and diagnostic workflows to support the introduction of next-generation targeted degraders into hematologic care. The data presented by Nurix exemplify how innovative mechanisms of action may disrupt traditional treatment pathways and highlight the need for updated guideline alignment, clinician training, and equitable access strategies for advanced therapeutics in rare B-cell malignancies.
With strong early efficacy, durable responses, and a consistent safety profile, bexobrutideg emerges as a promising next-generation therapy for Waldenström macroglobulinemia and potentially other B-cell cancers. As Nurix advances its clinical programs and expands development across hematologic and immune-mediated diseases, the Phase 1 data presented at ASH signal a significant milestone in the rise of targeted protein degradation as a transformative biopharma platform.
Source: Nurix Therapeutics, Inc. press release
